These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 39034222)

  • 1. Socioeconomic and Demographic Disparities in Immunotherapy Utilization for Advanced Kidney and Bladder Cancer.
    Holland L; Bhanvadia R; Ibeziako N; Taylor J; Gerlt D; Chaplin I; Bagrodia A; Desai N; Gaston K; Lotan Y; Margulis V; Zhang T; Cole S; Woldu S
    Urol Oncol; 2024 Nov; 42(11):374.e11-374.e20. PubMed ID: 39034222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US.
    Ermer T; Canavan ME; Maduka RC; Li AX; Salazar MC; Kaminski MF; Pichert MD; Zhan PL; Mase V; Kluger H; Boffa DJ
    JAMA Netw Open; 2022 Jun; 5(6):e2219535. PubMed ID: 35771575
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discrepancies in staging, treatment, and delays to treatment may explain disparities in bladder cancer outcomes: An update from the National Cancer Data Base (2004-2013).
    Weiner AB; Keeter MK; Manjunath A; Meeks JJ
    Urol Oncol; 2018 May; 36(5):237.e9-237.e17. PubMed ID: 29338913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy, immunotherapy, or combination first-line treatment for metastatic urothelial carcinoma of the bladder: A large real-world experience.
    Ranganathan S; Riveros C; Xu J; Hu S; Geng M; Huang E; Melchiode Z; Zhang J; Efstathiou E; Chan KS; Wallis CJD; Sonpavde G; Satkunasivam R
    Urol Oncol; 2024 Sep; 42(9):291.e13-291.e25. PubMed ID: 38763801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative real-world survival outcomes of metastatic papillary and clear cell renal cell carcinoma treated with immunotherapy, targeted therapy, and combination therapy.
    Riveros C; Ranganathan S; Xu J; Chang C; Kaushik D; Morgan M; Miles BJ; Muhammad T; Anis M; Aghazadeh M; Zhang J; Efstathiou E; Klaassen Z; Brooks MA; Rini B; Wallis CJD; Satkunasivam R
    Urol Oncol; 2023 Mar; 41(3):150.e1-150.e9. PubMed ID: 36610815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Racial inequity and other social disparities in the diagnosis and management of bladder cancer.
    Hasan S; Lazarev S; Garg M; Mehta K; Press RH; Chhabra A; Choi JI; Simone CB; Gorovets D
    Cancer Med; 2023 Jan; 12(1):640-650. PubMed ID: 35674112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Area Vulnerability and Disparities in Therapy for Patients With Metastatic Renal Cell Carcinoma.
    Rahman SN; Long JB; Westvold SJ; Leapman MS; Spees LP; Hurwitz ME; McManus HD; Gross CP; Wheeler SB; Dinan MA
    JAMA Netw Open; 2024 Apr; 7(4):e248747. PubMed ID: 38687479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiology and treatment patterns for locally advanced or metastatic urothelial carcinoma: a systematic literature review and gap analysis.
    Hepp Z; Shah SN; Smoyer K; Vadagam P
    J Manag Care Spec Pharm; 2021 Feb; 27(2):240-255. PubMed ID: 33355035
    [No Abstract]   [Full Text] [Related]  

  • 9. Improved survival after cytoreductive nephrectomy for metastatic renal cell carcinoma in the contemporary immunotherapy era: An analysis of the National Cancer Database.
    Singla N; Hutchinson RC; Ghandour RA; Freifeld Y; Fang D; Sagalowsky AI; Lotan Y; Bagrodia A; Margulis V; Hammers HJ; Woldu SL
    Urol Oncol; 2020 Jun; 38(6):604.e9-604.e17. PubMed ID: 32253116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes of stage IV melanoma in the era of immunotherapy: a National Cancer Database (NCDB) analysis from 2014 to 2016.
    Sussman TA; Knackstedt R; Wei W; Funchain P; Gastman BR
    J Immunother Cancer; 2022 Aug; 10(8):. PubMed ID: 35998982
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: analysis of the National Cancer Database.
    Gupta A; Omeogu C; Islam JY; Joshi A; Zhang D; Braithwaite D; Karanth SD; Tailor TD; Clarke JM; Akinyemiju T
    Sci Rep; 2023 May; 13(1):8190. PubMed ID: 37210410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inequity in selective referral to high-volume hospitals for genitourinary malignancies.
    Berg S; Tully KH; Sahraoui A; Tan WS; Krimphove MJ; Marchese M; Lipsitz SR; Noldus J; Trinh QD
    Urol Oncol; 2020 Jun; 38(6):582-589. PubMed ID: 32217041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Socioeconomic Factors Affect Presentation Stage and Survival in Sinonasal Squamous Cell Carcinoma.
    Jafari A; Shen SA; Qualliotine JR; Lehmann AE; Humphreys IM; Abuzeid WM; Bergmark RW; Gray ST
    Laryngoscope; 2021 Nov; 131(11):2421-2428. PubMed ID: 33844294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Demographic Factors Associated With Non-Guideline-Based Treatment of Kidney Cancer in the United States.
    Howard JM; Nandy K; Woldu SL; Margulis V
    JAMA Netw Open; 2021 Jun; 4(6):e2112813. PubMed ID: 34106265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US.
    Moyers JT; Patel A; Shih W; Nagaraj G
    JAMA Netw Open; 2020 Sep; 3(9):e2015656. PubMed ID: 32876684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
    Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
    Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns of immunotherapy utilization for non-small cell lung cancer in Texas pre- and post-regulatory approval.
    Olateju OA; Zeng Z; Zakeri M; Sansgiry SS
    Clin Transl Oncol; 2024 Aug; 26(8):1908-1920. PubMed ID: 38554190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Race, ethnicity, and socioeconomic factors in cholangiocarcinoma: What is driving disparities in receipt of treatment?
    Lee RM; Liu Y; Gamboa AC; Zaidi MY; Kooby DA; Shah MM; Cardona K; Russell MC; Maithel SK
    J Surg Oncol; 2019 Sep; 120(4):611-623. PubMed ID: 31301148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
    Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
    Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends and Disparities in Next-Generation Sequencing in Metastatic Prostate and Urothelial Cancers.
    Hage Chehade C; Jo Y; Gebrael G; Tripathi N; Sayegh N; Chigarira B; Mathew Thomas V; Galarza Fortuna G; Narang A; Campbell P; Gupta S; Maughan BL; Roy S; Agarwal N; Swami U
    JAMA Netw Open; 2024 Jul; 7(7):e2423186. PubMed ID: 39023888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.